Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.
Increased expression of glucose transporters has been reported in many cancers. It is not known whether Sodium dependent GLucose Transporter 1 (SGLT1) is up-regulated in pancreatic cancer. We studied the expression of SGLT1, Bcl-2 and p53 in primary pancreatic adenocarcinomas related to survival. In primary tumors, mean SGLT1-Hscore (n = 83) was 4.24 (median 3.0, range 0.5-15.0). Patients with positive staining for Bcl-2 had higher mean SGLT1-Hscores than those without Bcl-2 expression: 5.87 vs. 3.07 (P = 0.025). No correlation was found between expression of p53 and SGLT1 (P = 0.881). On multivariate analysis TNM stage (P = 0.015) and SGLT1 (P = 0.030) showed prognostic value for disease free survival (DFS). For overall survival (OS), TNM stage (P<0.001) and chemotherapy (P = 0.048) were prognostic and SGLT1 showed a trend (P = 0.071). In a subgroup of younger patients (age < or = median, 63.9 y) who did not receive chemotherapy, SGLT1 was a very strong predictor of DFS (P = 0.005). We conclude that high SGLT1 expression (H score > median, 3.0) in pancreatic adenocarcinomas was significantly correlated with DFS and a trend was found for OS, especially in younger patients. High SGLT1 expression in primary tumors was correlated with high Bcl-2 expression, not with p53 expression. This supports our hypothesis that SGLT1 and Bcl-2 expression could serve as prognostic markers in pancreatic cancer.
Department of Gastroenterology, Ghent University Hospital De Pintelaan, Ghent, Belgium. Veerle.Casneuf@UGent.be
Veerle F
VF
Casneuf
Philippe
P
Fonteyne
Nancy
N
Van Damme
Pieter
P
Demetter
Patrick
P
Pauwels
Bernard
B
de Hemptinne
Martine
M
De Vos
Christophe
C
Van de Wiele
Marc
M
Peeters
D000230:Adenocarcinoma / Q000737:chemistry* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000737:chemistry / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002454:Cell Differentiation; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis* / Q000502:physiology; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis*; D051269:Sodium-Glucose Transporter 1 / Q000032:analysis* / Q000502:physiology; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; C495674:SLC5A1 protein, human; D051269:Sodium-Glucose Transporter 1; D016159:Tumor Suppressor Protein p53